Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Biomea Fusion, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
07/31/2023 8-K Quarterly results
07/25/2023 8-K Quarterly results
05/02/2023 8-K Quarterly results
05/02/2023 8-K Quarterly results
04/03/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between the Company and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Biomea Fusion Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif.,- March 29, 2023 - Biomea Fusion, Inc. , a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of the common stock in the proposed offering are being offered by Biomea. In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to...",
"Press Release issued by the Company on March 29, 2023"
03/28/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
01/12/2023 8-K Investor presentation
Docs: "Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones REDWOOD CITY, Calif., Jan. 9, 2023 — Biomea Fusion, Inc. , a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present recent progress and 2023 corporate milestones at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 from 11:15 - 11:55 am ET, and that Biomea management will hold 1x1 meetings during the conference January 9 - 11. A live webcast of the presentation will be available ...",
"Corporate Slide Presentation of Biomea Fusion, Inc., titled “JP Morgan 2023 Corporate Presentation”"
12/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes"
12/13/2022 8-K Investor presentation
Docs: "Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date",
"Presentation titled, “BMF-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML.”"
11/25/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Equity Distribution Agreement, by and between the Company and Piper Sandler & Co",
"Opinion of Goodwin Procter LLP as to the legality of the securities being registered"
11/07/2022 8-K Quarterly results
Docs: "Senior Vice President, Corporate"
10/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BMF-219 Enters the Clinic for KRAS Solid Tumors"
09/09/2022 8-K Quarterly results
08/29/2022 8-K Quarterly results
08/01/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of First Amendment to Change in Control and Severance Agreement"
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting",
"Poster presentation titled, “Irreversible Menin Inhibitor, BMF-219, Exhibits Potent Cytotoxicity in KRAS-Mutated Solid Tumors.”",
"Poster presentation titled, “Anti-tumor Activity of Irreversible Menin Inhibitor, BMF-219, in High Grade B-Cell Lymphoma and Multiple Myeloma Preclinical Models.”",
"Poster presentation titled, “A Phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as a single agent in patients with relapsed/refractory (R/R) acute lymphocytic/acute myeloid leukemia (ALL/AML), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).”"
02/28/2022 8-K Quarterly results
Docs: "Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights"
01/12/2022 8-K Investor presentation
Docs: "Corporate Slide Presentation of Biomea Fusion, Inc. dated January 2022",
"Corporate Slide Presentation of Biomea Fusion, Inc. dated January 2022"
11/15/2021 8-K Investor presentation
Docs: "Corporate Slide Presentation of Biomea Fusion, Inc. dated November 2021"
11/03/2021 8-K Quarterly results
Docs: "Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights"
09/17/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
07/19/2021 8-K Quarterly results
07/09/2021 8-K Quarterly results
06/29/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
04/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy